scholarly journals Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: A novel molecule that induces autophagic cell death

Autophagy ◽  
2008 ◽  
Vol 4 (7) ◽  
pp. 944-946 ◽  
Author(s):  
Sandra Turcotte ◽  
Patrick D. Sutphin ◽  
Amato J. Giaccia
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Autophagic Cell Death ◽  
Von Hippel Lindau

scholarly journals 4-Pyridylanilinothiazoles That Selectively Target von Hippel−Lindau Deficient Renal Cell Carcinoma Cells by Inducing Autophagic Cell Death

2010 ◽  
Vol 53 (2) ◽  
pp. 787-797 ◽  
Author(s):  
Michael P. Hay ◽  
Sandra Turcotte ◽  
Jack U. Flanagan ◽  
Muriel Bonnet ◽  
Denise A. Chan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carcinoma Cells ◽  
Autophagic Cell Death ◽  
Von Hippel Lindau

scholarly journals Ubenimex enhances the radiosensitivity of renal cell carcinoma cells by inducing autophagic cell death

2016 ◽  
Vol 12 (5) ◽  
pp. 3403-3410 ◽  
Author(s):  
Shuai Liu ◽  
Xiaoqing Wang ◽  
Jiaju Lu ◽  
Liping Han ◽  
Yongfei Zhang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carcinoma Cells ◽  
Autophagic Cell Death

scholarly journals Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0200878 ◽  
Author(s):  
Leticia Serrano-Oviedo ◽  
Marta Ortega-Muelas ◽  
Jesús García-Cano ◽  
María Ll. Valero ◽  
Francisco J. Cimas ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Autophagic Cell Death

scholarly journals A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2

2020 ◽  
Vol 21 (7) ◽  
pp. 2493 ◽  
Author(s):  
Soo-Youl Kim ◽  
Jeffrey W. Keillor
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Hypoxia Inducible Factor ◽  
Physiological Role ◽  
Transglutaminase 2 ◽  
Cell Renal Cell Carcinoma ◽  
Von Hippel Lindau ◽  
High Level

In a recent report, no significance of transglutaminase 2 (TGase 2) was noted in the analyses of expression differences between normal and clear cell renal cell carcinoma (ccRCC), although we found that knock down of TGase 2 induced significant p53-mediated cell death in ccRCC. Generally, to find effective therapeutic targets, we need to identify targets that belong specifically to a cancer phenotype that can be differentiated from a normal phenotype. Here, we offer precise reasons why TGase 2 may be the first therapeutic target for ccRCC, according to several lines of evidence. TGase 2 is negatively regulated by von Hippel-Lindau tumor suppressor protein (pVHL) and positively regulated by hypoxia-inducible factor 1-α (HIF-1α) in renal cell carcinoma (RCC). Therefore, most of ccRCC presents high level expression of TGase 2 because over 90% of ccRCC showed VHL inactivity through mutation and methylation. Cell death, angiogenesis and drug resistance were specifically regulated by TGase 2 through p53 depletion in ccRCC because over 90% of ccRCC express wild type p53, which is a cell death inducer as well as a HIF-1α suppressor. Although there have been no detailed studies of the physiological role of TGase 2 in multi-omics analyses of ccRCC, a life-long study of the physiological roles of TGase 2 led to the discovery of the first target as well as the first therapeutic treatment for ccRCC in the clinical field.

scholarly journals Von Hippel-Lindau Gene Mutations and Vascular Endothelial Growth Factor Immunoexpression in Clear Cell Renal Cell Carcinoma

2019 ◽  
Vol 31 (2) ◽  
pp. 170-175
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Gene Mutations ◽  
Cell Renal Cell Carcinoma ◽  
Vhl Gene ◽  
Von Hippel Lindau ◽  
Clear Cell Rcc

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults representing about 3% of all newly diagnosed cancers in the United States. Clear cell RCC is the most common subtype (70-80%) of RCC. Clear cell RCC can be familial, but 95% of cases are sporadic resulting from the germline or acquired mutation of Von Hippel-Lindau (VHL) gene. VHL tumor suppressor gene functions as a down regulator of vascular endothelial growth factor (VEGF). Mutations of VHL gene result in overexpression of VEGF, neoangiogenesis and tumor metastasis. Nowadays, anti-VEGF targeted therapy is used for treating metastasis clear cell RCC. However, drug resistance occurs over time. VHL gene targeted therapy combined with anti-VEGF therapy should be considered and detection of VHL gene mutations status becomes essential in these cases. The present study was aimed to detect the VHL gene mutations status and VEGF immunoexpression in 62 clear cell RCC patients by conventional polymerase chain reaction and immunohistochemistry. Three primer pairs were used to detect the mutations of 3 exons in VHL gene. The positive cases for VHL exon 1 mutation, exon 2 mutation and exon 3 mutation were checked by 2% agarose gel electrophoresis. Tumor grading was done by Fuhrman nuclear grading system and staging was done by pathologic TNM staging system. Fifty cases (80.65%) were VHL gene mutation positive and 12 cases (19.35%) were negative. VHL gene mutations were significantly associated with histological grades (p=0.005). Out of 62 cases, 24 cases were weakly positive (1+) and 38 cases were strongly positive (2+) VEGF immuno-reactivity. There was statistically significant association between VEGF immunoexpression and histological grades of clear cell renal cell carcinoma (p=0.00) as well as tumor stage (p=0.01). It was also found that VEGF immunoexpression of clear cell RCC was significantly associated with VHL gene mutation positive tumours (p=0.00). These results can be helpful in further invention of molecular targeted therapy for drug-resistant clear cell RCC patients.

scholarly journals Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Yongchang Lai ◽  
Tao Zeng ◽  
Xiongfa Liang ◽  
Weizou Wu ◽  
Fangling Zhong ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell
Sign in / Sign up

Export Citation Format

Share Document